Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

被引:91
作者
Ganbaatar, Byambasuren [1 ]
Fukuda, Daiju [2 ]
Shinohara, Masakazu [3 ,4 ]
Yagi, Shusuke [1 ]
Kusunose, Kenya [1 ]
Yamada, Hirotsugu [5 ]
Soeki, Takeshi [1 ]
Hirata, Ken-ichi [6 ]
Sata, Masataka [1 ]
机构
[1] Tokushima Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[2] Tokushima Univ, Dept Cardiodiabet Med, Grad Sch Biomed Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan
[3] Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
[5] Tokushima Univ, Dept Community Med Cardiol, Grad Sch Biomed Sci, Tokushima 7708503, Japan
[6] Kobe Univ, Div Cardiovasc Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan
关键词
Atherosclerosis; Inflammation; Endothelial function; SGLT2; inhibitor; Empagliflozin; PERIVASCULAR ADIPOSE-TISSUE; SGLT2; INHIBITOR; MORTALITY; ATHEROSCLEROSIS; PHENOTYPE; DISEASE; ROLES; AGES;
D O I
10.1016/j.ejphar.2020.173040
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent studies reported cardioprotective effects of sodium glucose co-transporter 2 (SGLT2) inhibitors; however, the underlying mechanisms are still obscure. Here, we investigated whether empagliflozin attenuates atherogenesis and endothelial dysfunction in diabetic apolipoprotein E-deficient (ApoE(-/-)) mice. Male streptozotocin (STZ) - induced diabetic ApoE(-/-) mice were treated with empagliflozin for 12 or 8 weeks. Empagliflozin lowered blood glucose (P < 0.001) and lipid levels in diabetic ApoE / mice. Empagliflozin treatment for 12 weeks significantly decreased atherosclerotic lesion size in the aortic arch (P < 0.01) along with reduction of lipid deposition (P < 0.05), macrophage accumulation (P < 0.001), and inflammatory molecule expression in plaques compared with the untreated group. Empagliflozin treatment for 8 weeks significantly ameliorated diabetes-induced endothelial dysfunction as determined by the vascular response to acetylcholine (P < 0.001). Empagliflozin reduced RNA expression of a macrophage marker, CD68, and inflammatory molecules such as MCP-1 (P < 0.05) and NADPH oxidase subunits in the aorta compared with the untreated group. Empagliflozin also reduced plasma levels of vasoconstrictive eicosanoids, prostaglandin E-2 and thromboxane B-2 (P < 0.001), which were elevated in diabetic condition. Furthermore, empagliflozin attenuated RNA expression of inflammatory molecules in perivascular adipose tissue (PVAT), suggesting the reduction of inflammation in PVAT. In in vitro studies, methylglyoxal (MGO), a precursor of AGEs, significantly increased the expression of inflammatory molecules such as MCP-1 and TNF-alpha in a murine macrophage cell line, RAW264.7. Our results indicated that empagliflozin attenuated endothelial dysfunction and atherogenesis in diabetic ApoE(-/-) mice. Reduction of vasoconstrictive eicosanoids and inflammation in the vasculature and PVAT may have a role as underlying mechanisms at least partially.
引用
收藏
页数:9
相关论文
共 54 条
[1]   SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice [J].
Al-Sharea, Annas ;
Murphy, Andrew J. ;
Huggins, L. A. ;
Hu, Y. ;
Goldberg, Ira J. ;
Nagareddy, Prabhakara R. .
ATHEROSCLEROSIS, 2018, 271 :166-176
[2]  
[Anonymous], 2017, INT J MOL SCI
[3]  
Bagi Zsolt, 2006, Pharmacol Rep, V58 Suppl, P52
[4]   Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition [J].
Basu, Debapriya ;
Huggins, Lesley-Ann ;
Scerbo, Diego ;
Obunike, Joseph ;
Mullick, Adam E. ;
Rothenberg, Paul L. ;
Di Prospero, Nicholas A. ;
Eckel, Robert H. ;
Goldberg, Ira J. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (09) :2207-2216
[5]   Exercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function [J].
Boa, B. C. S. ;
Yudkin, J. S. ;
van Hinsbergh, V. W. M. ;
Bouskela, E. ;
Eringa, E. C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (20) :3466-3481
[6]   SGLT2 inhibition - a novel strategy for diabetes treatment [J].
Chao, Edward C. ;
Henry, Robert R. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) :551-559
[7]   Proinflammatory Phenotype of Perivascular Adipocytes Influence of High-Fat Feeding [J].
Chatterjee, Tapan K. ;
Stoll, Lynn L. ;
Denning, Gerene M. ;
Harrelson, Allan ;
Blomkalns, Andra L. ;
Idelman, Gila ;
Rothenberg, Florence G. ;
Neltner, Bonnie ;
Romig-Martin, Sara A. ;
Dickson, Eric W. ;
Rudich, Steven ;
Weintraub, Neal L. .
CIRCULATION RESEARCH, 2009, 104 (04) :541-U237
[8]   Role of endothelial dysfunction in atherosclerosis [J].
Davignon, J ;
Ganz, P .
CIRCULATION, 2004, 109 (23) :27-32
[9]   Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice [J].
Dimitriadis, Georgios K. ;
Nasiri-Ansari, Narjes ;
Agrogiannis, Georgios ;
Kostakis, Ioannis D. ;
Randeva, Manpal S. ;
Nikiteas, Nikolaos ;
Patel, Vanlata H. ;
Kaltsas, Gregory ;
Papavassiliou, Athanasios G. ;
Randeva, Harpal S. ;
Kassi, Eva .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2019, 494
[10]   Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets [J].
Drummond, Grant R. ;
Selemidis, Stavros ;
Griendling, Kathy K. ;
Sobey, Christopher G. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :453-471